Age-adjusted charlson comorbidity score is associated with treatment decisions and clinical outcomes for patients undergoing radical cystectomy for bladder cancer

Cancer

Volumn 112, Issue 11, 2008, Pages 2384-2392

  Koppie, Theresa M ^a   Serio, Angel M ^a   Vickers, Andrew J ^a   Vora, Kinjal ^a   Dalbagni, Guido ^a   Donat, S Machele ^a   Herr, Harry W ^a   Bochner, Bernard H ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Bladder cancer; Comorbidity; Cystectomy; Disease progression; Survival analysis

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGE; AGE ADJUSTED CHARLSON COMORBIDITY INDEX; AGED; ARTICLE; BLADDER CARCINOMA; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ASSESSMENT; CLINICAL DECISION MAKING; CLINICAL FEATURE; COMORBIDITY; CYSTECTOMY; DISEASE COURSE; DISEASE FREE SURVIVAL; DISEASE SEVERITY; FEMALE; HUMAN; INSTITUTIONAL CARE; LYMPH NODE; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSTOPERATIVE CARE; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; SCORING SYSTEM; STATISTICAL MODEL; SURVIVAL TIME; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME; AGING; BLADDER TUMOR; CLINICAL TRIAL; MIDDLE AGED; MORTALITY; PATHOLOGY; PHYSIOLOGY; RISK FACTOR; SURVIVAL RATE;

AGED; AGED, 80 AND OVER; AGING; CARCINOMA, TRANSITIONAL CELL; COMORBIDITY; CYSTECTOMY; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 52049099393     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23462     Document Type: Article

References (26)

1. Doll R, Peto R. The causes of cancer - quantitative estimates of avoidable risks of cancer in the United States today. J Natl Cancer Inst. 1981;66:1191-1308.
2. Hammond EC, Horn D. Smoking and death rates: report on forty-four months of follow-up of 187,783 men. II. Death rates by cause. JAMA. 1958;166:1294-1308.
3. Bjerregaard BK, Raaschou-Nielsen O, Sorensen M, et al. Tobacco smoke and bladder cancer - in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer. 2006;119:2412-2416.
4. Nielsen ME, Shariat SF, Karakiewicz PI, et al. Advanced age is associated with poorer bladder cancer-specific survival in patients treated with radical cystectomy. Eur Urol. 2007;51:699-706; discussion 706-708.
5. Miller DC, Taub DA, Dunn RL, Montie JE, Wei JT. The impact of co-morbid disease on cancer control and survival following radical cystectomy. J Urol. 2003;169:105-109.
6. Satagopan JM, Ben-Porat L, Berwick M, Robson M, Kutler D, Auerbach AD. A note on competing risks in survival data analysis. Br J Cancer. 2004;91:1229-1235.
7. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999; 94:496-509.
8. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16: 1141-1154.
9. Herr H, Lee C, Chang S, Lerner S;Bladder Cancer Collaborative Group. Standardization of radical cystectomy and pelvic lymph node dissection for bladder cancer: a collaborative group report. J Urol. 2004;171:1823-1828; discussion 1827-1828.
10. Hafron J, Mitra N, Dalbagni G, Bochner B, Herr H, Donat SM. Does body mass index affect survival of patients undergoing radical or partial cystectomy for bladder cancer? J Urol. 2005;173:1513-1517.
11. Yancik R. Cancer burden in the aged: an epidemiologic and demographic overview. Cancer. 1997;80:1273-1283.
12. Ouellette JR, Small DG, Termuhlen PM. Evaluation of Charlson-Age Comorbidity Index as predictor of morbidity and mortality in patients with colorectal carcinoma. J Gastrointest Surg. 2004;8:1061-1067.
13. Reid BC, Alberg AJ, Klassen AC, et al. Comorbidity and survival of elderly head and neck carcinoma patients. Cancer. 2001;92:2109-2116.
14. Birim O, Kappetein AP, Goorden T, van Klaveren RJ, Bogers AJ. Proper treatment selection may improve survival in patients with clinical early-stage nonsmall cell lung cancer. Ann Thorac Surg. 2005;80:1021-1026.
15. Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J. The impact of co-morbidity on life expectancy among men with localized prostate cancer. J Urol. 1996;156:127-132.
16. Truong PT, Kader HA, Lacy B, et al. The effects of age and comorbidity on treatment and outcomes in women with endometrial cancer. Am J Clin Oncol. 2005;28:157-164.
17. Gettman MT, Boelter CW, Cheville JC, Zincke H, Bryant SC, Blute ML. Charlson co-morbidity index as a predictor of outcome after surgery for renal cell carcinoma with renal vein, vena cava or right atrium extension. J Urol. 2003;169: 1282-1286.
18. Tammemagi CM, Neslund-Dudas C, Simoff M, Kvale P. Impact of comorbidity on lung cancer survival. Int J Cancer. 2003;103:792-802.
19. Trimble EL, Carter CL, Cain D, Freidlin B, Ungerleider RS, Friedman MA. Representation of older patients in cancer treatment trials. Cancer. 1994;74(7 suppl):2208-2214.
20. Farnham SB, Cookson MS, Alberts G, Smith JA Jr, Chang SS. Benefit of radical cystectomy in the elderly patient with significant co-morbidities. Urol Oncol. 2004;22:178-181.
21. Hollenbeck BK, Miller DC, Taub D, et al. Aggressive treatment for bladder cancer is associated with improved overall survival among patients 80 years old or older. Urology. 2004;64:292-297.
22. Prout GR Jr, Wesley MN, Yancik R, Ries LA, Havlik RJ, Edwards BK. Age and comorbidity impact surgical therapy in older bladder carcinoma patients: a population-based study. Cancer. 2005;104:1638-1647.
23. Dash A, Galsky MD, Vickers AJ, et al. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer. 2006;107:506-513.
24. Koppie TM, Vickers AJ, Vora K, Dalbagni G, Bochner BH. Standardization of pelvic lymphadenectomy performed at radical cystectomy: can we establish a minimum number of lymph nodes that should be removed? Cancer. 2006;107: 2368-2374.
25. Bochner BH, Cho D, Herr HW, Donat M, Kattan MW, Dalbagni G. Prospectively packaged lymph node dissections with radical cystectomy: evaluation of node count variability and node mapping. J Urol. 2004;172(4 pt 1):1286-1290.
26. Leissner J, Ghoneim MA, Abol-Enein H, et al. Extended radical lymphadenectomy in patients with urothelial bladder cancer: results of a prospective multicenter study. J Urol. 2004;171:139-144.